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Abstract
Background: The present study determined the incidence of rifampicin resistance M. tuberculosis among outpatients at
the General Hospital Yauri, Kebbi State, Nigeria.
Materials and Methods: The study is a cross-sectional study conducted from February 2018 to October 2019.
Sociodemographic data were collected from hospital registration books. Rifampicin resistance M. tuberculosis was
detected using GeneXpert Model GX-IV following manufacturers' instruction. Descriptive statistics and logistic
regression were computed using SPSS version 20. The results were presented as odds ratios with associated 95%
confidence intervals, and P-value at 0.05.
Result: Of the 837 samples, 65.8% (551/837) were males, and 34.2% (286/837) females, 11.4% (95/837) HIV-
seropositive. M. tuberculosis was detected in 15.5% (130/837), of which 116/130 (89.23%) were males and 14/130
(10.77%) females. M. tuberculosis-HIV coinfection was detected in 9.47% (9/95) of HIV positive. Rifampicin
resistance was observed in 1.3% (11/837), 7.7% (10/130) in M. tuberculosis patients and 1.05% (1/94) in HIV
seropositive. In logistic regression, the odds ratio for having a rifampicin-resistant M. tuberculosis was 0.49 (0.15-1.54)
for > 30 years; taking <30 years as the reference value, 1.02 (1.00-1.03) for male; taking female as the reference value,
and 0.78 (0.09-6.15) for HIV positive, taking negative as the reference value.
Conclusion: This study reported the current incidence rate of rifampicin-resistant M. tuberculosis at the General
Hospital Yelwa Yauri, Kebbi State, Nigeria, among presumptive TB patients. Patients diagnosed with rifampicin-
resistant M. tuberculosis were predominantly male adults. Thus, frequent screening is vital for surveillance and reduces
the risk of transmission and spread ofM. tuberculosis infections.
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List of Abbreviations: HIV: Human immunodeficiency virus, MDR-TB: Multidrug-resistant tuberculosis, MTB: M.
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quality assurance, WHO: World Health Organization, SPSS: Statistical package for social sciences.
Introduction
The spread of multidrug-resistant tuberculosis (MDR-TB) remains a public health problem in Nigeria (Audu
et al., 2017). The country is among the high-TB-endemic in the world. An estimated 4.3% of tuberculosis patients in
the country are MDR, out of which 32% are newly diagnosed (WHO, 2016; Ukwamedua et al., 2019). A recent
national survey in Nigeria recorded a 2% increase in the prevalence of MDR-TB among pretreatment cases (Onyedum
et al., 2017). In Kebbi State, comprehensive information about the patterns of multidrug-resistant tuberculosis is
lacking, and only a few studies have assessed the extent of multidrug-resistant tuberculosis among likely TB patients in
other states of the federation ( Aminu and Tukur, 2017; Onyedum et al., 2017).
Rifampicin and isoniazid are essential drugs in the treatment of tuberculosis. The two drugs are critical for short-term
treatment with reduced toxicity because of long-term therapy ( WHO, 2016; Ukwamedua et al., 2019). Studies have
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shown that MDR-TB to rifampicin is accompanied mainly by resistance only to isoniazid (WHO, 2016; Ukwamedua et
al., 2019).
In the last few decades, culture is the most common laboratory diagnostic technique for M. tuberculosis (Ma et
al., 2006; Derseh et al., 2017). The technique requires sophisticated and expensive biosafety laboratory facilities
(Arega et al., 2019). Of recent, Gene Xpert assay, an automated molecular assay detects mutations on the rpoB gene
responsible for 90% cases of rifampicin-resistance in TB patients with less sophisticated facilities (Okonkwo et al.,
2017; Onyedum et al., 2017). Thus, the treatment of M. tuberculosis without susceptibility testing increases the risk of
transmission and spread of MDR-TB strains in a population ( Xiao-li et al., 2014; Onyedum et al., 2017; WHO, 2018).
With the projected incidence of 219 new TB cases per 100,000 people per year in the country (Onyedum et al.,
2017; Ukwamedua et al., 2019), screening for rifampicin-resistance tuberculosis within the population is vital for the
treatment of MDR-TB. This study will provide up-to-date insight into the incidence and extent of rifampicin-resistance
among likely TB patients in one of the referral hospitals in Kebbi State of Nigeria.
Materials and Methods
Study design, area and period
The study was conducted at General Hospital Yelwa Yauri, an Emirate Region situated in the southern part of
Kebbi State, Nigeria, between February 2018 to October 2019. In Yelwa Yauri, 54% of the populations live in rural
areas, and half of the communities are illiterates. The hospital is a secondary level health facility located in the heart of
the town.
Study design and Data collection
Participants microbiological and clinical information were collected from the hospital records for all the
presumptive patients. Patients' records with incomplete data, e.g., age, gender, Xpert MTB/RIF results, and HIV status
and unsuccessful results were excluded from the study. Failed results were classified as invalid, error and undetermined.
The inclusion criteria for this study included participants willing to provide their samples freely and those who
presented themselves as patients with a long-term duration of cough and chest pain and patients that are booked for
AFB screening.
Gene Xpert assay
Single sputum samples per patient were used for the diagnosis of Mycobacterium tuberculosis using Gene
Xpert assay. Samples were processed using Model GX-IV of the Gene Xpert (Cepheid Sunnyvale, CA, USA)
following the manufacturer's instruction. Briefly, 0.5 ml sputum sample and Xpert sample reagent were added in a ratio
of 1:2, vortex twice for 15 min at room temperature. Consequently, 2 ml of the reaction mixture was transferred to the
Xpert test cartridge; the cartridge was then loaded into the Xpert machine for 90 mins. The results were interpreted
from measured fluorescent signals automatically as MTB detected, not detected and if present- rifampicin resistant.
Data processing and statistical analysis
The database was generated in Microsoft Excel (Microsoft Corp., Redmond, WA, USA). Descriptive analysis
was adopted using the Statistical Package for the Social Sciences (SPSS®, version 21; SPSS Inc., Chicago, IL, USA).
Frequencies and percentages were calculated, and odds ratio and nominal 95% confidence intervals (CI) were presented
to explain the association between variables - age, gender, marital status, RIF resistance and HIV status independently
as against MTB detection. A two-sided p-value < 0.05 was considered significant.
Ethical issue
This study was approved by the ethical research and review committee of the Ministry of Health Birnin Kebbi,
Kebbi State, Nigeria (KSUSTA1510204007), on 02/05/2019.
Results
Of the 896 patients that submitted samples for TB diagnosis, 82.2% (837/896) were included in the study. Five
samples were external quality assurance (EQA) samples, 21 samples were invalid, 19 were error, and the remaining 14
samples were undetermined. Out of these 837, 65.8 % (551/837) were males, and 34.2 % (286/837) were females. The
study population median age was 35 years, 27.7% (232/837) were in the age range of 21–30 years, while 2.4% (20/837)
were in the age range under ten years. Among total study participants, 11.4% (95/837) were HIV-seropositive, and the
remaining 88.6% (742/837) were HIV-seronegative (Table 1).
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Table 1: Sociodemographic distribution and clinical characteristics
of tuberculosis patients in (N = 837)
Variables Total Patients Percentage %
Age















Not Detected 707 84.5
RIF Resistant
Detected 11 1.3




Among the enrolled presumptive TB patients, MTB was detected in 15.5% (130/837), of which 116/130
(89.23%) were males, and 14/130 (10.77%) were females. Of presumptive MTB patients, the age group 31–40 years
with a median age of 35 years, found prone to MTB infection 40/130 (30.8%). MTB-HIV coinfection was detected in
9.47% (9/95) of HIV positive patients, table 2. Rifampicin-resistant was observed in 1.3% (11/837) in the presumptive
TB patient, while the total RIF-MTB was 7.7% (10/130) in all MTB detected patients and 1.05% (1/94) in HIV
seropositive patient (Table 2).
Table 2: Characterization of M. tuberculosis in presumptive TB patients based on age, gender, HIV status and marital
status in Kebbi State, Nigeria (N = 837)
Variables Detected Not Detected OR(95%CI) P_Value
Age* MTB
Under 10 3 17 00*
11-20 6 99 0.35(.08-1.50)
21-30 33 199 0.94(0.26-3.39)
31-40 40 136 1.67(0.47-6.0)
41-50 25 118 1.20(0.33-4.41)
51-60 13 87 0.85(0.22-3.30)
Above 60 10 51 1.11(0.28-4.51)
Gender* MTB
Male 116 435 0.19(0.11-0.34) .000
Female 14 272 00*
Marital Status* MTB
Single 18 215 00*
Married 112 492 0.37(0.22-0.62) .000
RIF Resistant* MTB
Detected 10 120 0.02(0.002-0.13)
Not Detected 1 706 00*
HIV Status* MTB
Positive 9 121 1.86(0.91-3.8) 0.09
Negative 86 621 00*
00* = Reference category
MTB = M. tuberculosis
OR: Odd ratio
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In a logistic regression model, taking <30 years as the reference value, the odds ratio for having a rifampicin-
resistant MTB was 0.49 (95% CI, 0.15-1.54) for age groups > 30 years, 1.02 (95% CI, 1.00-1.03) for male taking
female as the reference value. It is 1.75 (95% CI, 0.33-8.17) for married, single as a reference value, and 0.78 (95% CI,
0.09-6.15) for HIV positive individuals, taking negative as the reference value (Table 3).
Table 3: Characterization of rifampicin-resistant M. tuberculosis in presumptive TB patients based on age, gender,
HIV status and Marital Status in Kebbi State, Nigeria (N = 837) .
Variables Detected Not Detected OR(95%CI) P_Value
Age* RIF
<30 years 4 353 00*
> 30 years 7 473 0.49(0.15-1.54) 0.29
Gender* RIF
Male 11 540 1.02(1.00-1.03) 0.02
Female 0 286 00*
Marital Status* RIF
Single 2 231 00*
Married 9 395 1.75(0.33-8.17) 0.74
HIV Status* RIF
Positive 1 94 0.78(0.09-6.15) 1.00
Negative 10 732 00*
00* = Reference category
Discussion
The spread of rifampicin resistant M. tuberculosis is a threat to treatment and control of tuberculosis
(Onyedum et al., 2017; WHO, 2018). Thus, early detection is essential for the management and prevention of
transmission of the disease. In the present study, we combined sociodemographic data and Xpert MTB/RIF assay and
assessed the incidence of rifampicin resistant Mycobacterium tuberculosis among outpatients referred to the General
Hospital Yauri, Kebbi State, Nigeria. This study is first to describe the scale of M. tuberculosis cases in the study
population.
The overall incidence rate of new M. tuberculosis cases in Yauri Emirate in Kebbi State was 15.5%. The result
was slightly higher than the studies reported in Zaria (12%) in the North-west region of the country a decade ago
( Ogboi et al., 2010). Though, the incidence is significantly lower than reports from previous studies in a referral
hospital in South-west Nigeria (37.7%) (Adejumo et al., 2018) and among patients previously treated for pulmonary
tuberculosis in North-west of Nigeria (29.2%). The incidence is equally lower than it has been reported in another study
in Nasarawa State in the North-central (18.8 %) (Audu et al., 2017). This result is considerably lower when compared
with the results obtained using a line probe assay from a referral hospital in Kano State (54.5 %) (Aminu and Tukur,
2017). The low incidence rate reported in this study compared with other studies could be attributed to sampling
techniques, size and methodology adopted.
Similarly, this study reported a 1.3% incidence rate of rifampicin resistance (11/ 837). The rate is significantly
lower than the 7.2% reported in Kwara State, Nigeria, 6.9% recorded in Nnewi, Nigeria (Dim and Dim, 2013;
Okonkwo et al., 2017). Also, the incidence rate is relatively below the projected rate of 3.2–5.4% for the country
( WHO, 2016; WHO, 2018). Although the resistance in this study is very low due to the sample size. The low incidence
rate recorded may be due to (i) this study considered only presumptive TB cases from outpatients using gene Xpert
assay, (ii) the rifampicin resistance positive cases recorded were infected with a resistant M. tuberculosis strain.
This study also found a high number of M. tuberculosis cases and rifampicin resistance among males compared to
females. All the 10 rifampicin-resistant M. tuberculosis were detected in presumptive TB patients. Analysis of
statistical significance reveals that gender is associated with rifampicin-resistant tuberculosis with p-values of 0.02. The
result was in line with a high rate of multidrug resistance TB reported in men in North and southern regions of Nigeria
( Iliyasu and Babashani, 2009; Derseh et al., 2017) and many African countries (Cox et al., 2010; Kirenga et al., 2015).
Also, the result was consistent with other studies that stated that the male gender is at risk of developing drug resistance
due to behavioural factors such as poor health-seeking behaviour, not finishing an antibiotic course and cultural
activities that expose male gender to infectious agents (Bello and Itiola, 2010).
The average age range with the highest rate of M. tuberculosis cases was 31-40 years, and rifampicin
resistance was in > 30 years. This result correlates with other studies reported in Nigeria, where patients between 20-40
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years had a higher prevalence of rifampicin resistance. However, the results disagree with studies that reported younger
age had been associated with PTB and MDR-PTB (Onyedum et al., 2017; Ukwamedua et al., 2019). The distinction
observed in this study was 48% of the total population in this study were adults between 20-40 years of age and 72.5%
rural farmers (data not shown) associated with unpasteurized cow milk in local porridge as a staple food in the farm.
The unpasteurized cow milk was the primary source of M. tuberculosis to the farmers (Araújo et al., 2014.; Lorente-
Leal et al., 2019).
The association between MTB-HIV coinfection has long been established (Oshi et al., 2014). Despite this, a
low rate of MTB-HIV coinfection was reported in this study. However, the reduced rates of MTB-HIV coinfection
recorded in this study may be because a significant number of the study participants had no contact with HIV because
of increasing public enlightenment in the population ( Keating et al., 2006; Gambo et al., 2013).
Conclusion
This study reported the current incidence rate of rifampicin-resistant M. tuberculosis at General Hospital
Yelwa Yauri Kebbi State, Nigeria, among possible M. tuberculosis. The patients diagnosed with rifampicin-resistant M.
tuberculosis were predominantly adult males. This result demonstrated that GeneXpert assay is a convenient tool for
the early diagnosis of rifampicin-resistant M. tuberculosis. Accordingly, frequent screening and surveillance within the
population are vital for the management and treatment ofM. tuberculosis infections.
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